CURE’s metastatic breast cancer page features the latest cancer news and updates on metastatic breast cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in metastatic breast cancer.
April 29th 2024
The FDA has approved Hercessi for the adjuvant treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Phase 3 Trial of Fablyn Plus Verzenio for Metastatic Breast Cancer Initiates Registration
March 20th 2023Pre- and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation are eligible to participate in the next round of Fablyn’s upcoming clinical trial.